Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.
about
Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disordersSelective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involvedFunctional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmissionComparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognitionA polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorderImaging the serotonin transporter during major depressive disorder and antidepressant treatmentA critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)'s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depressionInhibition of acid sphingomyelinase by tricyclic antidepressants and analogonsPharmacology of serotonin and female sexual behaviorPharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disordersA brief history of the development of antidepressant drugs: from monoamines to glutamateSerotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptorsSimilar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environmentsQuantitative cross-species extrapolation between humans and fish: the case of the anti-depressant fluoxetineAntidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal ModelsFluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell LinesPrenatal antidepressant exposure: clinical and preclinical findings.Diminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter.Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressantsApplication of palladium-mediated (18)F-fluorination to PET radiotracer development: overcoming hurdles to translation.Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomesSynthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emissionA comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels.3D-QSAR design of new escitalopram derivatives for the treatment of major depressive disorders.Role of the serotonergic system in reduced pulmonary function after exposure to methamphetamine.Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction.Trazodone effects on [H]-paroxetine and alpha(2)-adrenoreceptors in platelets of patients with major depression.Zebrafish Behavior in Novel Environments: Effects of Acute Exposure to Anxiolytic Compounds and Choice of Danio rerio Line.Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys.Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studiesDesigning human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulatorsAlcohol-induced depressive-like behavior is associated with cortical norepinephrine reduction.Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective 5-HT reuptake inhibitors on 5-HT release.Advances in the treatment of depressionSite-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transportersLithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus.Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants.Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT).A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.
P2860
Q21129108-593D13FF-C332-4110-A767-77D55F5BE994Q21129279-55874477-9758-462E-9B90-C6F86D88AA78Q23913269-66FFBC47-4171-49B4-B8A6-B999FBC53207Q24656589-DD956DFE-7935-49B6-AE7B-D27EB2878EA9Q24677816-DEA024C8-4718-4BAB-BB74-A427BBA00B6FQ24683135-812891BD-BA25-4DF4-9DDC-E6BADD9F2C62Q26796248-45507E38-BE3D-4CA4-8361-1C71F6797F76Q26852322-78112172-FF16-4F6A-A2B2-3A17B72469DCQ26861672-696DC299-C9AB-4C1C-982E-7194C59BC462Q27006437-6119ACCD-EAB0-4E26-BD3D-ECA593F4EAB8Q27028050-6EA7217A-8F92-49D6-99EB-D5276CE85BF5Q28344624-8618A6DB-9CD5-4BB4-A585-BCC93BCCA5CAQ28384182-D86F4456-21E8-4FC4-93A5-C11C38FBAF8FQ28543995-FFD21D76-EA7A-4D0C-8458-76641487F44CQ28550792-A10F2DD7-F8B6-414C-8990-D3B960ABDD50Q28554574-27E7B45F-EC67-4903-B6FA-841DDEF12400Q30415540-3549932F-37A7-4739-B5F6-8B093B690963Q30459642-85FC3865-4598-40EA-8135-7461D9BA3B80Q30887852-AAFC79EF-5238-4A33-A9AA-2E6BDA6BA4ADQ31114482-3E7CCB35-0FAD-4552-8616-3EB41F78475CQ33569581-7159B787-37F3-420D-B47A-EA9199477C0DQ33623987-8D31583B-3C24-4117-92B4-99A7B85FB685Q33718185-43FDBA60-855C-4034-98CB-5145EF59EBD8Q33742105-59287108-C417-4ED7-AEB2-6704906ED049Q33778302-C4E000F9-D534-42C9-B53F-7B0D0B5244E1Q33868543-3CB10822-ECB2-4DA4-AD8A-C9241FEAC842Q33874819-D07FE216-CEA7-4710-9E26-94E13FDD3D43Q33881541-C62EBE62-E314-45D1-864B-D847BDE6BFABQ33889976-74FFF064-2595-4ECD-B1EB-97E4BBBC661EQ34035262-B4F49DBC-347B-42F0-A8B3-579F7297A500Q34140313-83CCFC88-F695-42CC-BE60-3240EB7C5DBEQ34184921-525BACD6-2F80-45AE-9189-2FDF4C8EA3A3Q34259347-3F19A360-8D68-40EB-9968-3FB77C7E9512Q34442321-ADA0F48A-53E8-4A79-BE29-96D71248EC52Q34496251-CCB0070C-92C1-40B6-A7B1-9705165E4E1EQ34701009-EB667BBD-797B-4967-AAC8-539C13B8861FQ34715718-D4DB2820-1768-4165-B793-33667AFAEF88Q34943864-D673C9C3-520D-4FDC-93F2-262C364BFC64Q35047597-45C4264E-3BEA-46EF-ABB7-3C62C776ED8FQ35087700-79DB5F35-DCFC-4232-BEF2-BEAED0677FA9
P2860
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Neurotransmitter receptor and ...... essants and their metabolites.
@ast
Neurotransmitter receptor and ...... essants and their metabolites.
@en
Neurotransmitter receptor and ...... essants and their metabolites.
@nl
type
label
Neurotransmitter receptor and ...... essants and their metabolites.
@ast
Neurotransmitter receptor and ...... essants and their metabolites.
@en
Neurotransmitter receptor and ...... essants and their metabolites.
@nl
prefLabel
Neurotransmitter receptor and ...... essants and their metabolites.
@ast
Neurotransmitter receptor and ...... essants and their metabolites.
@en
Neurotransmitter receptor and ...... essants and their metabolites.
@nl
P2093
P1476
Neurotransmitter receptor and ...... essants and their metabolites.
@en
P2093
P304
P407
P577
1997-12-01T00:00:00Z